Peter Hulick to Retrospective Studies
This is a "connection" page, showing publications Peter Hulick has written about Retrospective Studies.
Connection Strength
0.143
-
Effects of Social Determinants and Pharmacogenetic Medication Interactions on 90-Day Hospital Readmissions. Ann Fam Med. 2024 Nov 01; 21(Suppl 3).
Score: 0.022
-
Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies. Prostate Cancer Prostatic Dis. 2022 09; 25(3):422-430.
Score: 0.019
-
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genet Med. 2021 09; 23(9):1726-1737.
Score: 0.018
-
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). JAMA Oncol. 2020 08 01; 6(8):1218-1230.
Score: 0.017
-
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genet Med. 2020 10; 22(10):1653-1666.
Score: 0.017
-
Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study. Cancer Med. 2019 09; 8(12):5609-5618.
Score: 0.016
-
Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 05; 71(5):740-747.
Score: 0.013
-
Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature. Ann Surg Oncol. 2015 Feb; 22(2):370-6.
Score: 0.011
-
Variable clinical presentation of an MUC1 mutation causing medullary cystic kidney disease type 1. Clin J Am Soc Nephrol. 2014 Mar; 9(3):527-35.
Score: 0.011